NASDAQ:BJDX Bluejay Diagnostics (BJDX) Stock Price, News & Analysis $1.31 -0.14 (-9.66%) As of 01:30 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Bluejay Diagnostics Stock (NASDAQ:BJDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bluejay Diagnostics alerts:Sign Up Key Stats Today's Range$1.25▼$1.3250-Day Range$1.14▼$5.3052-Week Range$1.03▼$16.68Volume502,621 shsAverage Volume1.92 million shsMarket Capitalization$1.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Bluejay Diagnostics, Inc. (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures. Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting. The company has been pursuing clinical validation studies and regulatory clearances to support its plans for commercialization, working to demonstrate accuracy, reliability, and ease of use in both clinical and at-home environments. Headquartered in Norcross, Georgia, Bluejay Diagnostics serves the U.S. market with strategic plans to expand internationally once regulatory approvals and distribution partnerships are in place. The management team brings together expertise in diagnostics, biotech development, and regulatory affairs, positioning the company to navigate the complex pathways associated with medical device registration and market entry. As Bluejay advances its development pipeline, it aims to improve patient access to timely, accurate, and patient-friendly diagnostic solutions for celiac disease and related disorders.AI Generated. May Contain Errors. Read More Bluejay Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreBJDX MarketRank™: Bluejay Diagnostics scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBluejay Diagnostics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBluejay Diagnostics has only been the subject of 1 research reports in the past 90 days.Read more about Bluejay Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bluejay Diagnostics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bluejay Diagnostics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBluejay Diagnostics has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bluejay Diagnostics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted46.83% of the float of Bluejay Diagnostics has been sold short.Short Interest Ratio / Days to CoverBluejay Diagnostics has a short interest ratio ("days to cover") of 1.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bluejay Diagnostics has recently increased by 156.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBluejay Diagnostics does not currently pay a dividend.Dividend GrowthBluejay Diagnostics does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.84 News SentimentBluejay Diagnostics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Bluejay Diagnostics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for BJDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $47,798.00 in company stock, which represents 3.6255% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Bluejay Diagnostics insiders have bought 97.72% more of their company's stock than they have sold. Specifically, they have bought $96,711.00 in company stock and sold $48,913.00 in company stock.Percentage Held by Insiders6.10% of the stock of Bluejay Diagnostics is held by insiders.Percentage Held by Institutions18.47% of the stock of Bluejay Diagnostics is held by institutions.Read more about Bluejay Diagnostics' insider trading history. Receive BJDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BJDX Stock News HeadlinesBluejay Diagnostics (NASDAQ:BJDX) Rating Increased to Sell at Wall Street ZenJuly 18 at 1:24 AM | americanbankingnews.comFinancial Lp Hrt Purchases 64,047 Shares of Bluejay Diagnostics (NASDAQ:BJDX) StockJuly 15, 2026 | americanbankingnews.com#1 Power Grid Stock Right NowThe U.S. power grid is under pressure, and one company's new technology is already deployed in remote fields in West Texas. The stock has drawn backing from Elon Musk and is positioned at the center of domestic grid modernization. A free video breaks down why analysts are calling it a top pick right now.July 20 at 1:00 AM | Altimetry (Ad)Financial Lp Hrt Sells 34,938 Shares of Bluejay Diagnostics (NASDAQ:BJDX) StockJuly 14, 2026 | insidertrades.comBluejay Diagnostics Advances Symphony IL-6 Sepsis Pilot, Keeping Investor Focus on ER DiagnosticsJuly 2, 2026 | tipranks.comBluejay Diagnostics, Inc. Closes $8.5 Million Private Placement to Extend Cash Runway for FDA Approval and CommercializationJune 5, 2026 | quiverquant.comQBluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq RulesJune 5, 2026 | globenewswire.comBluejay Nears Completion of Pivotal SYMON-II Sepsis TrialJune 5, 2026 | theglobeandmail.comSee More Headlines BJDX Stock Analysis - Frequently Asked Questions How have BJDX shares performed this year? Bluejay Diagnostics' stock was trading at $2.6688 at the start of the year. Since then, BJDX stock has decreased by 52.0% and is now trading at $1.28. How were Bluejay Diagnostics' earnings last quarter? Bluejay Diagnostics, Inc. (NASDAQ:BJDX) announced its earnings results on Thursday, May, 7th. The company reported ($1.95) EPS for the quarter. When did Bluejay Diagnostics' stock split? Shares of Bluejay Diagnostics reverse split on Thursday, June 20th 2024.The 1-8 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Bluejay Diagnostics IPO? Bluejay Diagnostics (BJDX) raised $0 in an IPO on Tuesday, November 9th 2021. The company issued 2,160,000 shares at $0.00 per share. How do I buy shares of Bluejay Diagnostics? Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bluejay Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bluejay Diagnostics investors own include SoFi Technologies (SOFI), V.F. (VFC), Allarity Therapeutics (ALLR), Andersons (ANDE) and British American Tobacco (BTI). Company Calendar Last Earnings5/07/2026Today7/20/2026Next Earnings (Estimated)8/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 3 weeks, BJDX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:BJDX CIK1704287 Webwww.bluejaydx.com Phone844-327-7078FaxN/AEmployees9Year Founded2015Profitability EPS (Trailing Twelve Months)($11.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-144.27% Return on Assets-115.00% Debt Debt-to-Equity RatioN/A Current Ratio2.81 Quick Ratio2.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.43 per share Price / Book0.16Miscellaneous Outstanding Shares1,030,000Free Float972,000Market Cap$1.35 million OptionableNot Optionable Beta0.88 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:BJDX) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...Chaikin Analytics | SponsoredSMX: From Under-the-Radar to Must-Watch!SMX (Security Matters) PLC is building Digital Material Passport technology that embeds molecular-level marker...Smallcaps Daily | SponsoredEx-CIA Insider: “Prepare for a Mid-Term Meltdown”Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...Paradigm Press | SponsoredAmerican’s Biggest Threat Is HereThis feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...Goldco Direct, LLC | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bluejay Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
